IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2017
This article has no abstract
Epistemonikos ID: f980bdefaf0c953e12aca5f727561cd1c572317f
First added on: Jul 10, 2018